CA2197319C
(en)
*
|
1994-08-29 |
2009-01-27 |
Louis S. Kucera |
Lipid analogs for treating viral infections
|
US7135584B2
(en)
*
|
1995-08-07 |
2006-11-14 |
Wake Forest University |
Lipid analogs for treating viral infections
|
UA72558C2
(uk)
*
|
1999-11-01 |
2005-03-15 |
Мерц Фарма Гмбх Унд Ко. Кгаа |
1-аміноалкілциклогексанові антагоністи рецептора nmda
|
US6444702B1
(en)
|
2000-02-22 |
2002-09-03 |
Neuromolecular, Inc. |
Aminoadamantane derivatives as therapeutic agents
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
NZ547204A
(en)
|
2000-05-26 |
2008-01-31 |
Idenix Cayman Ltd |
Methods and compositions for treating flaviviruses and pestiviruses
|
TW593223B
(en)
*
|
2000-06-20 |
2004-06-21 |
Merz Pharma Gmbh & Co Kgaa |
1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
|
US6602862B1
(en)
|
2000-09-19 |
2003-08-05 |
Merz Pharma Gmbh & Co., Kgaa |
1-Amino-alkylcyclohexanes as trypanocidal agents
|
CN1646141B
(zh)
|
2000-10-18 |
2014-06-25 |
吉利德制药有限责任公司 |
用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
|
WO2002044717A1
(en)
*
|
2000-12-01 |
2002-06-06 |
Cornell Research Foundation |
Animal model for flaviviridae infection
|
KR20030081343A
(ko)
*
|
2000-12-15 |
2003-10-17 |
파마셋, 리미티드 |
플라비비리다에 감염 치료용 항바이러스제
|
WO2002072542A2
(en)
*
|
2001-03-08 |
2002-09-19 |
Emory University |
Ph-dependent nmda receptor antagonists
|
EP1435974A4
(en)
*
|
2001-09-28 |
2006-09-06 |
Idenix Cayman Ltd |
METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
|
US6828462B2
(en)
*
|
2001-11-07 |
2004-12-07 |
Merz Pharma Gmbh & Co. Kgaa |
Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
|
BR0307712A
(pt)
*
|
2002-02-14 |
2005-05-24 |
Pharmasset Ltd |
Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
|
MXPA04012709A
(es)
|
2002-06-28 |
2005-09-30 |
Idenix Cayman Ltd |
Profarmacos modificados de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
|
TW200410672A
(en)
*
|
2002-07-19 |
2004-07-01 |
Merz Pharma Gmbh & Co Kgaa |
NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
|
MXPA05001298A
(es)
*
|
2002-08-01 |
2005-11-04 |
Pharmasset Inc |
Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae.
|
WO2004037234A2
(en)
|
2002-10-24 |
2004-05-06 |
Merz Pharma Gmbh & Co. Kgaa |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
WO2004046331A2
(en)
|
2002-11-15 |
2004-06-03 |
Idenix (Cayman) Limited |
2’-branched nucleosides and flaviviridae mutation
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
MXPA05012493A
(es)
*
|
2003-05-27 |
2006-05-25 |
Forest Laboratories |
Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
|
WO2005003147A2
(en)
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
ATE478886T1
(de)
|
2003-07-25 |
2010-09-15 |
Idenix Pharmaceuticals Inc |
Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
|
WO2005009421A2
(en)
*
|
2003-07-28 |
2005-02-03 |
Merz Pharma Gmbh & Co. Kgaa |
The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
|
EP1682109B1
(en)
*
|
2003-10-22 |
2008-10-15 |
Merz Pharma GmbH & Co. KGaA |
The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic as peptides in amyloidopathies
|
AR046314A1
(es)
|
2003-11-05 |
2005-11-30 |
Merz Pharma Gmbh & Co Kgaa |
Composiciones que comprenden ciclohexilaminas y aminoadamantanos
|
UY28650A1
(es)
*
|
2003-12-05 |
2005-02-28 |
Forest Laboratories |
Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
RS51540B
(en)
*
|
2004-01-05 |
2011-06-30 |
Merz Pharma Gmbh. & Co. Kgaa. |
MEMANTINE FOR THE TREATMENT OF Mild to Moderate Alzheimer's Disease
|
US20050187192A1
(en)
*
|
2004-02-20 |
2005-08-25 |
Kucera Pharmaceutical Company |
Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
|
US20050187191A1
(en)
*
|
2004-02-20 |
2005-08-25 |
Kucera Louis S. |
Methods and compositions for the treatment of respiratory syncytial virus
|
TW200531680A
(en)
*
|
2004-03-03 |
2005-10-01 |
Merz Pharma Gmbh & Co Kgaa |
Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
|
US20060002999A1
(en)
*
|
2004-06-17 |
2006-01-05 |
Forest Laboratories, Inc. |
Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
|
ES2483126T3
(es)
|
2004-06-17 |
2014-08-05 |
Merz Pharma Gmbh & Co. Kgaa |
Formulaciones de formas de dosificación de neramexano
|
JP2008503475A
(ja)
*
|
2004-06-17 |
2008-02-07 |
フォーレスト ラボラトリーズ, インコーポレイテッド |
メマンチンの放出が改変された製剤
|
WO2006000922A2
(en)
*
|
2004-06-23 |
2006-01-05 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
EP1809301B1
(en)
|
2004-09-14 |
2019-11-06 |
Gilead Pharmasset LLC |
2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
|
TW200621677A
(en)
*
|
2004-09-21 |
2006-07-01 |
Astellas Pharma Inc |
Cyclic amine derivative or salt thereof
|
US20060205822A1
(en)
*
|
2004-12-22 |
2006-09-14 |
Forest Laboratories, Inc. |
1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
|
EA013474B1
(ru)
*
|
2005-06-16 |
2010-04-30 |
Форест Лэборэтериз, Инк. |
Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
|
US20070099947A1
(en)
*
|
2005-11-03 |
2007-05-03 |
Alkermes, Inc. |
Methods and compositions for the treatment of brain reward system disorders by combination therapy
|
US20070141148A1
(en)
*
|
2005-11-30 |
2007-06-21 |
Merz Pharma Gmbh & Co. Kgaa |
Neramexane MR matrix tablet
|
EP2007789B1
(en)
|
2006-04-11 |
2015-05-20 |
Novartis AG |
Spirocyclic HCV/HIV inhibitors and their uses
|
WO2008005534A2
(en)
*
|
2006-07-06 |
2008-01-10 |
Forest Laboratories, Inc. |
Orally dissolving formulations of memantine
|
US8013018B2
(en)
|
2006-07-18 |
2011-09-06 |
Astellas Pharma Inc. |
Aminoindane derivative or salt thereof
|
BRPI0714622A2
(pt)
|
2006-08-04 |
2013-04-30 |
Merz Pharma Gmbh & Co Kgaa |
pirazolopirimidinas substituÍdas, processo para sua preparaÇço e seu uso como medicamento
|
WO2008055945A1
(en)
|
2006-11-09 |
2008-05-15 |
Probiodrug Ag |
3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
|
SI2091948T1
(sl)
|
2006-11-30 |
2012-07-31 |
Probiodrug Ag |
Novi inhibitorji glutaminil ciklaze
|
EP2144604B1
(en)
|
2007-02-28 |
2011-09-21 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
ZA200905537B
(en)
|
2007-03-01 |
2010-10-27 |
Probiodrug Ag |
New use of glutaminyl cyclase inhibitors
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
EP2142514B1
(en)
|
2007-04-18 |
2014-12-24 |
Probiodrug AG |
Thiourea derivatives as glutaminyl cyclase inhibitors
|
TW200916091A
(en)
*
|
2007-06-08 |
2009-04-16 |
Merz Pharma Gmbh & Amp Co Kgaa |
Neramexane for the treatment of nystagmus
|
KR20100045983A
(ko)
*
|
2007-06-29 |
2010-05-04 |
에모리 유니버시티 |
신경보호를 위한 nmda 수용체 길항물질
|
EP2018854A1
(en)
*
|
2007-07-27 |
2009-01-28 |
Merz Pharma GmbH & Co. KGaA |
Novel combinations of neramexane for the treatment of neurodegenerative disorders
|
RU2446794C2
(ru)
*
|
2007-09-12 |
2012-04-10 |
Мерц Фарма Гмбх Унд Ко. Кгаа |
Терапия с интервалами для лечения тиннитуса
|
EP2548552B1
(en)
*
|
2007-09-12 |
2015-11-18 |
Merz Pharma GmbH & Co. KGaA |
Titration package for 1-amino-alkylcyclohexanes
|
EP2085398A1
(en)
|
2008-02-01 |
2009-08-05 |
Merz Pharma GmbH & Co. KGaA |
Pyrazolopyrimidines, a process for their preparation and their use as medicine
|
EP2090576A1
(en)
|
2008-02-01 |
2009-08-19 |
Merz Pharma GmbH & Co.KGaA |
6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US20090247644A1
(en)
*
|
2008-03-28 |
2009-10-01 |
Forest Laboratories Holdings Limited |
Memantine formulations
|
WO2009128058A1
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
EP2111858A1
(en)
|
2008-04-25 |
2009-10-28 |
EPFL Ecole Polytechnique Fédérale de Lausanne |
Novel treatment for alzheimer's disease
|
US20090275597A1
(en)
*
|
2008-05-02 |
2009-11-05 |
Forest Laboratories Holdings Limited |
Methods of treating cns disorders
|
US8173621B2
(en)
*
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
TW201010691A
(en)
*
|
2008-06-12 |
2010-03-16 |
Merz Pharma Gmbh & Co Kgaa |
1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
|
TW201006463A
(en)
*
|
2008-06-26 |
2010-02-16 |
Merz Pharma Gmbh & Co Kgaa |
Pharmaceutical compositions comprising aminocyclohexane derivatives
|
ES2458358T3
(es)
|
2008-07-02 |
2014-05-05 |
Idenix Pharmaceuticals, Inc. |
Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
EP2373304B1
(en)
|
2008-12-19 |
2014-07-30 |
Merz Pharma GmbH & Co. KGaA |
Neramexane for the treatment of mast cell mediated diseases
|
TWI432188B
(zh)
|
2008-12-19 |
2014-04-01 |
Merz Pharma Gmbh & Co Kgaa |
供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類
|
US8716263B2
(en)
|
2008-12-23 |
2014-05-06 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
EP3222628A1
(en)
|
2008-12-23 |
2017-09-27 |
Gilead Pharmasset LLC |
Nucleoside phosphoramidates
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US8784847B2
(en)
*
|
2009-04-17 |
2014-07-22 |
Merz Pharma Gmbh & Co. Kgaa |
Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
EP2448911A1
(en)
|
2009-06-29 |
2012-05-09 |
Merz Pharma GmbH & Co. KGaA |
Method of preparing 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane
|
WO2011000536A1
(en)
|
2009-06-29 |
2011-01-06 |
Merz Pharma Gmbh & Co. Kgaa |
Method of preparing 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane
|
JP5749261B2
(ja)
*
|
2009-06-29 |
2015-07-15 |
メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー |
3,3,5,5−テトラメチルシクロヘキサノンを調製する方法
|
TW201116532A
(en)
|
2009-08-05 |
2011-05-16 |
Merz Pharma Gmbh & Co Kgaa |
Metabotropic glutamate receptor modulators
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
ES2548913T3
(es)
|
2009-09-11 |
2015-10-21 |
Probiodrug Ag |
Derivados heterocíclicos como inhibidores de glutaminil ciclasa
|
JP2013505902A
(ja)
*
|
2009-09-28 |
2013-02-21 |
メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン |
ネラメキサン又はその塩を調製する方法
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
CA2784748A1
(en)
|
2009-12-18 |
2011-06-23 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
JP5688745B2
(ja)
|
2010-03-10 |
2015-03-25 |
プロビオドルグ エージー |
グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
|
PT3290428T
(pt)
|
2010-03-31 |
2021-12-27 |
Gilead Pharmasset Llc |
Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
WO2011123586A1
(en)
|
2010-04-01 |
2011-10-06 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
US20110294890A1
(en)
|
2010-05-28 |
2011-12-01 |
Merz Pharma Gmbh & Co. Kgaa |
Neramexane for the treatment or prevention of inner ear disorders
|
EP2582356A1
(en)
*
|
2010-06-18 |
2013-04-24 |
Merz Pharma GmbH & Co. KGaA |
Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives
|
US9011833B2
(en)
|
2010-10-08 |
2015-04-21 |
Novartis Ag |
Vitamin E formulations of sulfamide NS3 inhibitors
|
WO2012048871A1
(en)
|
2010-10-12 |
2012-04-19 |
Merz Pharma Gmbh & Co. Kgaa |
Memantine for improving cognitive performance in subjects
|
AU2011336632B2
(en)
|
2010-11-30 |
2015-09-03 |
Gilead Pharmasset Llc |
Compounds
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
JP6084931B2
(ja)
|
2011-01-20 |
2017-02-22 |
メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン |
ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
|
TW201309690A
(zh)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
|
WO2012107584A1
(en)
|
2011-02-11 |
2012-08-16 |
Universite Pierre Et Marie Curie (Paris 6) |
Methods for predicting outcome of a hepatitis virus infection
|
WO2012123563A1
(en)
|
2011-03-16 |
2012-09-20 |
Probiodrug Ag |
Benz imidazole derivatives as inhibitors of glutaminyl cyclase
|
EP2691409B1
(en)
|
2011-03-31 |
2018-02-21 |
Idenix Pharmaceuticals LLC. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
KR20140063657A
(ko)
|
2011-08-03 |
2014-05-27 |
사이세리스 |
Hcv 면역요법
|
AU2012308900A1
(en)
|
2011-09-12 |
2013-05-09 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
TW201329096A
(zh)
|
2011-09-12 |
2013-07-16 |
Idenix Pharmaceuticals Inc |
經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
|
TW201331221A
(zh)
|
2011-10-14 |
2013-08-01 |
Idenix Pharmaceuticals Inc |
嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US9089574B2
(en)
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
WO2013133927A1
(en)
|
2012-02-13 |
2013-09-12 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
EP2852603B1
(en)
|
2012-05-22 |
2021-05-12 |
Idenix Pharmaceuticals LLC |
D-amino acid compounds for liver disease
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
RU2488388C1
(ru)
*
|
2012-05-24 |
2013-07-27 |
Ооо "Валента Интеллект" |
Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
|
UA107653U
(uk)
|
2012-10-01 |
2016-06-24 |
Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" |
Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
|
CN111848711A
(zh)
|
2012-10-08 |
2020-10-30 |
埃迪尼克斯医药有限责任公司 |
用于hcv感染的2′-氯核苷类似物
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
EP4005560A1
(en)
|
2013-08-27 |
2022-06-01 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
EP3063165A1
(en)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
WO2015134561A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
JP2020505439A
(ja)
|
2017-01-10 |
2020-02-20 |
オーウェン−バリー・ファーマシューティカルズ・インコーポレイテッドOwen−Barry Pharmaceuticals Inc. |
抗痙攣薬化合物
|
EP3461819B1
(en)
|
2017-09-29 |
2020-05-27 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
WO2023154014A1
(en)
|
2022-02-08 |
2023-08-17 |
Sahin Fikret |
Nmdar antagonists prevent ageing and aging-associated conditions and diseases through increasing 20s proteasome activity
|